EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-Inflammatory Oxysterol, Oxy210, Inhibits Atherosclerosis in Hyperlipidemic Mice and Inflammatory Responses of Vascular Cells

Frank Stappenbeck, Feng Wang, Satyesh K Sinha, Simon T Hui, Lia Farahi, Nigora Mukhamedova, Andrew Fleetwood iD, Andrew J Murphy iD, Dmitri Sviridov iD, Aldons J Lusis iD, Farhad Parhami iD

Cells · 30.09.2024 · 13 (19) · 1632

DOI: 10.3390/cells13191632 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 30.09.2024. Verfasst von Frank Stappenbeck und 10 weiteren Autor:innen. Beteiligte Einrichtung: MAX BioPharma Inc., Santa Monica, CA 90404, USA. Hauptthemen laut MEDLINE: Atherosclerosis, Inflammation, Endothelial Cells, Oxysterols. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, SBIR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims: We previously reported that Oxy210, an oxysterol-based drug candidate, exhibits antifibrotic and anti-inflammatory properties. We also showed that, in mice, it ameliorates hepatic hallmarks of non-alcoholic steatohepatitis (NASH), including inflammation and fibrosis, and reduces adipose tissue inflammation. Here, we aim to investigate the effects of Oxy210 on atherosclerosis, an inflammatory disease of the large arteries that is linked to NASH in epidemiologic studies, shares many of the same risk factors, and is the major cause of mortality in people with NASH.

Methods

Oxy210 was studied in vivo in APOE*3-Leiden.CETP mice, a humanized mouse model for both NASH and atherosclerosis, in which symptoms are induced by consumption of a high fat, high cholesterol “Western” diet (WD). Oxy210 was also studied in vitro using two cell types that are important in atherogenesis: human aortic endothelial cells (HAECs) and macrophages treated with atherogenic and inflammatory agents.

Results

Oxy210 reduced atherosclerotic lesion formation by more than 50% in hyperlipidemic mice fed the WD for 16 weeks. This was accompanied by reduced plasma cholesterol levels and reduced macrophages in lesions. In HAECs and macrophages, Oxy210 reduced the expression of key inflammatory markers associated with atherosclerosis, including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), chemokine (C-C motif) ligand 2 (CCL2), vascular cell adhesion molecule-1 (VCAM-1), and E-Selectin. In addition, cholesterol efflux was significantly enhanced in macrophages treated with Oxy210.

Conclusions

These findings suggest that Oxy210 could be a drug candidate for targeting both NASH and atherosclerosis, as well as chronic inflammation associated with the manifestations of metabolic syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisInflammationEndothelial CellsOxysterolsAnti-Inflammatory AgentsAnimalsMiceHumansHyperlipidemiasMacrophagesMaleDisease Models, AnimalDiet, High-Fat

Stichwörter der Autor:innen

APOE*3-Leiden.CETP mouse modelMAFLD/MASHNAFLD/NASHOxy210atherosclerosischronic inflammationendothelial cellsfibrosismacrophagesoxysterols

Substanzen

OxysterolsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • MAX BioPharma Inc., Santa Monica, CA 90404, USA.
  • Department of Medicine, Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
  • Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
  • Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3168, Australia.

ORCID-Profile: Andrew Fleetwood, Andrew J Murphy, Dmitri Sviridov, Aldons J Lusis, Farhad Parhami

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • SBIR
  • National Heart, Lung, and Blood Institute (NHLBI), and SBIR
  • National Institute of Diabetes and Digestive Kidney Diseases (NIDDK) awarded to MAX BioPharma.
  • NHLBI
  • NIDDK

Zitieren

APA

Stappenbeck, F., Wang, F., Sinha, S. K., Hui, S. T., Farahi, L., Mukhamedova, N., Fleetwood, A., Murphy, A. J., Sviridov, D., Lusis, A. J., & Parhami, F. (2024). Anti-Inflammatory Oxysterol, Oxy210, Inhibits Atherosclerosis in Hyperlipidemic Mice and Inflammatory Responses of Vascular Cells. Cells, 13(19), 1632. https://doi.org/10.3390/cells13191632

Vancouver

Stappenbeck F, Wang F, Sinha SK, Hui ST, Farahi L, Mukhamedova N, et al. Anti-Inflammatory Oxysterol, Oxy210, Inhibits Atherosclerosis in Hyperlipidemic Mice and Inflammatory Responses of Vascular Cells. Cells. 2024;13(19):1632. doi:10.3390/cells13191632

BibTeX
@article{Stappenbeck2024,
  author = {Stappenbeck, Frank and Wang, Feng and Sinha, Satyesh K and Hui, Simon T and Farahi, Lia and Mukhamedova, Nigora and Fleetwood, Andrew and Murphy, Andrew J and Sviridov, Dmitri and Lusis, Aldons J and Parhami, Farhad},
  title = {Anti-Inflammatory Oxysterol, Oxy210, Inhibits Atherosclerosis in Hyperlipidemic Mice and Inflammatory Responses of Vascular Cells},
  journal = {Cells},
  year = {2024},
  volume = {13},
  number = {19},
  pages = {1632},
  doi = {10.3390/cells13191632}
}
Kostenlos starten →